Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Revenio Group Oyj Director's Dealing 2022

Aug 5, 2022

3236_dirs_2022-08-05_d706e0a7-a5d2-4ba3-8e3f-1290ac62e024.pdf

Director's Dealing

Open in viewer

Opens in your device viewer

Revenio Group Corporation: Managers' Transactions – Robin Pulkkinen

Revenio Group Corporation, Managers' transactions, August 5, 2022 at 5.30 p.m. (EEST)

Revenio Group Oyj: Managers' Transactions – Robin Pulkkinen

____________________________________________

Person subject to the notification requirement Name: Robin Pulkkinen Position: Chief Financial Officer Issuer: Revenio Group Oyj LEI: 743700I27E0FWSXLKK04 Notification type: INITIAL NOTIFICATION Reference number: 18240/7/6

____________________________________________

Transaction date: 2022-08-04 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI0009010912 Nature of the transaction: DISPOSAL

Transaction details (1): Volume: 200 Unit price: 53 EUR (2): Volume: 505 Unit price: 54.6 EUR (3): Volume: 250 Unit price: 53.2 EUR (4): Volume: 200 Unit price: 55 EUR (5): Volume: 200 Unit price: 54 EUR Aggregated transactions (5): Volume: 1355 Volume weighted average price: 54.07601 EUR

For further information, please contact

CFO Robin Pulkkinen, tel. +358 50 505 9932 [email protected] www.revenio.fi

Distribution Nasdaq Helsinki Ltd Main media www.revenio.fi

Revenio Group in brief

Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio's ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand. iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care.

In 2021, the Group's net sales totaled EUR 78.8 million, with an operating profit of EUR 22.1 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Attachments

Revenio Group Corporation: Managers' Transactions – Robin Pulkkinen